About Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).
Industry, Sector and Symbol
Trailing P/E Ratio17.32
Forward P/E Ratio14.28
Sales & Book Value
Annual Sales$1.49 billion
Price / Sales5.56
Cash Flow$8.89 per share
Price / Cash15.52
Book Value$41.19 per share
Price / Book3.35
Net Income$396.83 million
Return on Equity22.92%
Return on Assets10.07%
Frequently Asked Questions for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
What is Jazz Pharmaceuticals PLC's stock symbol?
Jazz Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "JAZZ."
How were Jazz Pharmaceuticals PLC's earnings last quarter?
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) posted its earnings results on Tuesday, August, 9th. The specialty pharmaceutical company reported $2.63 earnings per share for the quarter, missing analysts' consensus estimates of $2.80 by $0.17. The specialty pharmaceutical company had revenue of $381 million for the quarter, compared to analysts' expectations of $376.40 million. Jazz Pharmaceuticals PLC had a return on equity of 22.92% and a net margin of 23.58%. The firm's revenue was up 14.2% on a year-over-year basis. During the same quarter last year, the company posted $2.41 EPS. View Jazz Pharmaceuticals PLC's Earnings History.
When will Jazz Pharmaceuticals PLC make its next earnings announcement?
What guidance has Jazz Pharmaceuticals PLC issued on next quarter's earnings?
Jazz Pharmaceuticals PLC issued an update on its FY17 earnings guidance on Tuesday, November, 7th. The company provided earnings per share guidance of $10.70-11.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.89. The company issued revenue guidance of $1.60-1.65 billion, compared to the consensus revenue estimate of $1.64 billion.
Where is Jazz Pharmaceuticals PLC's stock going? Where will Jazz Pharmaceuticals PLC's stock price be in 2017?
21 Wall Street analysts have issued 12 month price objectives for Jazz Pharmaceuticals PLC's shares. Their predictions range from $150.00 to $210.00. On average, they expect Jazz Pharmaceuticals PLC's stock price to reach $181.71 in the next year. View Analyst Ratings for Jazz Pharmaceuticals PLC.
What are Wall Street analysts saying about Jazz Pharmaceuticals PLC stock?
Here are some recent quotes from research analysts about Jazz Pharmaceuticals PLC stock:
- 1. According to Zacks Investment Research, "Jazz reported mixed results in the third quarter of 2017 with earnings beating estimates while revenues missing the same. The company lowered its earnings guidance for 2017, mainly due to lower-than-expected sales from Xyrem. The drug also is facing patent challenges in the United States. Moreover, restricted access to distribution channels for Xyrem is another matter of concern. Additionally, Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug, Erwinaze, due to constrained manufacturing capacity. The company has its share of pipeline setbacks too. However, its lead pipeline candidate, JZP-110, currently evaluated for treatment of EDS, complements its existing sleep disorder portfolio. Nonetheless, the FDA approval of, Vyxeos in August, lends huge boost to the company, given its huge commercial potential in the target market." (11/10/2017)
- 2. Cantor Fitzgerald analysts commented, "Meetings highlight view that late-stage assets are underappreciated. We hosted meetings with the CEO in the Midwest last week. Investors he met with expressed interest in Xyrem, of course, but the bulk of the questions centered around the pipeline. A common theme was that JZP-110 may be underestimated by the Street. We also spoke with some investors who seem to be gaining appreciation for the potential of the low-sodium oxybate formulations. Vyxeos approval could be around the corner. The PDUFA date for Vyxeos is September 30, and management commented that Breakthrough-designated drugs have been approved before the statutory date." (6/27/2017)
- 3. Mizuho analysts commented, "We raise our PT to $162 from $152 while reiterating our Buy rating following positive Phase III data in a key pipeline drug (JZP-110) in obstructive sleep apnea. Our PT went up due to increased likelihood of FDA approval." (3/21/2017)
- 4. Cowen Inc analysts commented, "complete re-rating."Cacciatore comments, "We continue to believe Jazz is nearing a very interesting inflection point, as a favorable resolution to the Xyrem litigation is likely, which could extend the franchise to 2024/2025. Combined with JZP-110's potential $750MM+ opportunity to complement growing Defitelio, Erwinaze, and ultimately Vyxeos, we believe a complete re-rating is nearing. We would add here." (3/20/2017)
- 5. BMO Capital Markets analysts commented, "JAZZ delivered on an important milestone with positive Phase 3 data for JZP-110 in two OSA studies that appear to demonstrate a very solid clinical profile for this novel wake-promoting agent. There had been some concerns into these data (first OSA studies for JZP-110), and we think this outcome significantly de-risks the program; Phase 3 data in narcolepsy set for 2Q17 and filing in late 2017. We reiterate our Outperform; JAZZ remains a top pick." (3/20/2017)
Who are some of Jazz Pharmaceuticals PLC's key competitors?
Some companies that are related to Jazz Pharmaceuticals PLC include Grifols, S.A. (GRFS), ProMetic Life Sciences (PLI), Sirtex Medical Limited (SRX), Theratechnologies (TH), Mirati Therapeutics (MRTX), Siga Technologies (SIGA), OrganiGram Holdings (OGI), VBI Vaccines (VBIV), XOMA Corporation (XOMA), Osiris Therapeutics (OSIR), Anavex Life Sciences Corp. (AVXL), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), ContraFect Corporation (CFRX), Concordia International Corp. (CXR), Soligenix (SNGX), Senesco Technologies (SVON) and Mateon Therapeutics (MATN).
Who owns Jazz Pharmaceuticals PLC stock?
Jazz Pharmaceuticals PLC's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (2.47%), Westfield Capital Management Co. LP (2.40%), Amundi Pioneer Asset Management Inc. (1.48%), Janus Henderson Group PLC (1.42%), Orbimed Advisors LLC (1.25%) and American Century Companies Inc. (1.05%). Company insiders that own Jazz Pharmaceuticals PLC stock include Bruce C Cozadd, Heather Ann Mcsharry, Iain Mcgill, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals PLC.
Who sold Jazz Pharmaceuticals PLC stock? Who is selling Jazz Pharmaceuticals PLC stock?
Jazz Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, RK Capital Management LLC, Canada Pension Plan Investment Board, Monarch Partners Asset Management LLC, KBC Group NV, Janus Henderson Group PLC, Zurcher Kantonalbank Zurich Cantonalbank and DekaBank Deutsche Girozentrale. Company insiders that have sold Jazz Pharmaceuticals PLC company stock in the last year include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.
Who bought Jazz Pharmaceuticals PLC stock? Who is buying Jazz Pharmaceuticals PLC stock?
Jazz Pharmaceuticals PLC's stock was acquired by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Westfield Capital Management Co. LP, Bank of New York Mellon Corp, Orbimed Advisors LLC, Virginia Retirement Systems ET AL, American Century Companies Inc., Asset Management One Co. Ltd. and APG Asset Management N.V.. Company insiders that have bought Jazz Pharmaceuticals PLC stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.
How do I buy Jazz Pharmaceuticals PLC stock?
Shares of Jazz Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jazz Pharmaceuticals PLC's stock price today?
One share of Jazz Pharmaceuticals PLC stock can currently be purchased for approximately $138.04.
How big of a company is Jazz Pharmaceuticals PLC?
Jazz Pharmaceuticals PLC has a market capitalization of $8.28 billion and generates $1.49 billion in revenue each year. The specialty pharmaceutical company earns $396.83 million in net income (profit) each year or $6.07 on an earnings per share basis. Jazz Pharmaceuticals PLC employs 1,040 workers across the globe.
How can I contact Jazz Pharmaceuticals PLC?
Jazz Pharmaceuticals PLC's mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at firstname.lastname@example.org.
MarketBeat Community Rating for Jazz Pharmaceuticals PLC (JAZZ)MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 5 Hold Ratings, 16 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.76)|
|Consensus Price Target: ||$181.71 (31.64% upside)|
Consensus Price Target History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Analysts' Ratings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
(Data available from 11/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/10/2017||HC Wainwright||Reiterated Rating||Neutral -> Neutral||$144.00 -> $150.00||N/A|
|11/8/2017||Wells Fargo & Company||Reiterated Rating||Outperform||$177.00 -> $172.00||N/A|
|11/8/2017||Royal Bank Of Canada||Lower Price Target||Outperform||$210.00 -> $195.00||N/A|
|10/26/2017||Stifel Nicolaus||Reiterated Rating||Buy||$190.00||N/A|
|10/23/2017||Cowen Inc||Set Price Target||Buy||$190.00||N/A|
|10/21/2017||Piper Jaffray Companies||Set Price Target||Buy||$177.00||N/A|
|10/19/2017||FBR & Co||Initiated Coverage||Buy -> Buy||$206.00||N/A|
|10/5/2017||Morgan Stanley||Initiated Coverage||Equal -> Equal Weight||$155.00||N/A|
|9/28/2017||Goldman Sachs Group, Inc. (The)||Initiated Coverage||Neutral -> Neutral||$165.00||Low|
|9/20/2017||BMO Capital Markets||Reiterated Rating||Buy||$196.00||High|
|9/18/2017||J P Morgan Chase & Co||Reiterated Rating||Buy||$190.00||Low|
|8/29/2017||Cantor Fitzgerald||Reiterated Rating||Buy||Low|
|8/9/2017||Deutsche Bank AG||Set Price Target||Buy||$178.00 -> $175.00||High|
|8/9/2017||Janney Montgomery Scott||Reiterated Rating||Buy||$180.00 -> $192.00||Low|
|7/4/2017||Mizuho||Downgrade||Buy -> Neutral||$162.00 -> $150.00||Low|
|7/4/2017||Leerink Swann||Boost Price Target||Buy||$169.00 -> $170.00||Low|
|5/22/2017||Sanford C. Bernstein||Set Price Target||Market Perform||$160.00 -> $176.00||Low|
|2/22/2017||Evercore ISI||Initiated Coverage||Buy||$160.00||N/A|
|1/19/2017||SunTrust Banks, Inc.||Reiterated Rating||Buy||$210.00||N/A|
|1/18/2017||Barclays PLC||Reiterated Rating||Overweight||$200.00||N/A|
|4/5/2016||Canaccord Genuity||Reiterated Rating||Buy||$170.00||N/A|
|4/1/2016||Northland Securities||Reiterated Rating||Outperform||$175.00||N/A|
Earnings History and Estimates Chart for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Earnings History by Quarter for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/27/2018|| || || || || || || || |
|8/8/2017||6/30/2017||$1.85||$1.72||$410.83 million||$394.39 million||View||Listen|
|5/9/2017||3/31/2017||$1.42||$1.41||$376.58 million||$376.10 million||View||Listen|
|2/28/2017||Q416||$2.65||$1.91||$398.91 million||$396.62 million||View||Listen|
|11/8/2016||Q316||$2.61||$2.16||$389.34 million||$374.00 million||View||Listen|
|8/9/2016||Q216||$2.80||$2.63||$376.40 million||$381.00 million||View||N/A|
|5/10/2016||Q1||$2.31||$2.26||$338.86 million||$336.00 million||View||Listen|
|2/23/2016||Q415||$2.60||$2.60||$349.98 million||$340.90 million||View||Listen|
|11/9/2015||Q315||$2.56||$2.52||$348.15 million||$340.90 million||View||Listen|
|8/5/2015||Q215||$2.41||$2.41||$335.58 million||$333.70 million||View||Listen|
|5/7/2015||Q115||$2.15||$1.99||$309.50 million||$309.30 million||View||Listen|
|2/24/2015||Q414||$2.30||$2.44||$319.74 million||$328.10 million||View||Listen|
|11/4/2014||Q314||$1.98||$2.33||$302.90 million||$306.58 million||View||Listen|
|8/5/2014||Q214||$1.92||$2.05||$273.39 million||$291.23 million||View||Listen|
|5/8/2014||Q114||$1.79||$1.61||$254.86 million||$247.00 million||View||Listen|
|2/25/2014||Q413||$1.78||$1.72||$238.12 million||$235.80 million||View||Listen|
|11/5/2013||Q313||$1.67||$1.78||$227.38 million||$232.20 million||View||Listen|
|8/6/2013||Q2 2013||$1.52||$1.43||$208.71 million||$208.30 million||View||Listen|
|5/7/2013||Q1 2013||$1.35||$1.37||$189.92 million||$196.20 million||View||Listen|
|2/26/2013||Q4 2012||$1.41||$1.53||$183.80 million||$183.70 million||View||Listen|
|11/8/2012||Q312||$1.31||$1.29||$178.57 million||$175.50 million||View||N/A|
Earnings Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 90.52%
Insider Trades by Quarter for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/17/2017||Iain Mcgill||SVP||Sell||8,000||$133.42||$1,067,360.00|| |
|11/17/2017||Patrick G Enright||Director||Sell||352||$133.19||$46,882.88|| |
|10/2/2017||Bruce C Cozadd||CEO||Sell||1,000||$150.00||$150,000.00|| |
|9/12/2017||Bruce C. Cozadd||CEO||Sell||1,000||$153.52||$153,520.00|| |
|8/25/2017||Patrick G Enright||Director||Sell||351||$148.40||$52,088.40|| |
|8/15/2017||Michael Patrick Miller||EVP||Sell||200||$144.38||$28,876.00|| |
|8/14/2017||Paul Treacy||SVP||Sell||1,304||$143.32||$186,889.28|| |
|8/11/2017||Paul L Berns||Director||Sell||662||$142.37||$94,248.94|| |
|7/20/2017||Suzanne Sawochka Hooper||EVP||Sell||4,580||$160.00||$732,800.00|| |
|7/17/2017||Michael Patrick Miller||EVP||Sell||200||$154.97||$30,994.00|| |
|6/23/2017||Suzanne Sawochka Hooper||EVP||Sell||420||$160.00||$67,200.00|| |
|6/15/2017||Michael Patrick Miller||EVP||Sell||200||$150.65||$30,130.00|| |
|6/1/2017||Rick E Winningham||Director||Sell||5,000||$150.00||$750,000.00|| |
|5/15/2017||Michael Patrick Miller||EVP||Sell||200||$152.98||$30,596.00|| |
|5/11/2017||Bruce C Cozadd||CEO||Sell||30,000||$153.47||$4,604,100.00|| |
|5/9/2017||Suzanne Sawochka Hooper||EVP||Sell||2,500||$160.00||$400,000.00|| |
|4/27/2017||Karen J Wilson||SVP||Sell||1,275||$160.00||$204,000.00|| |
|4/27/2017||Suzanne Sawochka Hooper||EVP||Sell||2,500||$160.00||$400,000.00|| |
|4/17/2017||Michael Patrick Miller||SVP||Sell||200||$152.56||$30,512.00|| |
|4/11/2017||Bruce C Cozadd||CEO||Sell||1,000||$152.12||$152,120.00|| |
|4/10/2017||Karen J Wilson||SVP||Sell||11,458||$152.24||$1,744,365.92|| |
|3/15/2017||Michael Patrick Miller||SVP||Sell||200||$137.89||$27,578.00|| |
|3/6/2017||Paul Treacy||SVP||Sell||884||$131.97||$116,661.48|| |
|2/15/2017||Michael Patrick Miller||SVP||Sell||200||$134.55||$26,910.00|| |
|1/18/2017||Russell J. Cox||COO||Sell||4,000||$128.75||$515,000.00|| |
|1/17/2017||Michael Patrick Miller||SVP||Sell||200||$115.93||$23,186.00|| |
|12/15/2016||Michael Patrick Miller||SVP||Sell||200||$103.09||$20,618.00|| |
|12/2/2016||Patrick G Enright||Director||Sell||677||$101.80||$68,918.60|| |
|11/15/2016||Michael Patrick Miller||SVP||Sell||200||$112.19||$22,438.00|| |
|11/14/2016||Kenneth W O'keefe||Director||Buy||2,000||$113.84||$227,680.00|| |
|10/17/2016||Michael Patrick Miller||SVP||Sell||200||$118.16||$23,632.00|| |
|9/19/2016||Michael Patrick Miller||SVP||Sell||200||$126.17||$25,234.00|| |
|8/25/2016||Seamus Mulligan||Director||Sell||27,968||$128.32||$3,588,853.76|| |
|8/16/2016||Paul Treacy||SVP||Sell||1,292||$137.47||$177,611.24|| |
|8/15/2016||Michael Patrick Miller||SVP||Sell||100||$136.45||$13,645.00|| |
|8/15/2016||Rick E Winningham||Director||Sell||633||$136.45||$86,372.85|| |
|8/12/2016||Karen L Smith||Insider||Buy||608||$137.10||$83,356.80|| |
|8/9/2016||Bruce C. Cozadd||CEO||Sell||1,000||$150.00||$150,000.00|| |
|8/9/2016||Russell J. Cox||COO||Sell||4,000||$148.66||$594,640.00|| |
|7/15/2016||Michael Patrick Miller||SVP||Sell||100||$142.43||$14,243.00|| |
|7/13/2016||Karen L Smith||CMO||Buy||580||$143.63||$83,305.40|| |
|6/15/2016||Michael Patrick Miller||SVP||Sell||100||$149.64||$14,964.00|| |
|6/13/2016||Karen L Smith||CMO||Buy||557||$149.61||$83,332.77|| |
|5/16/2016||Heather Ann Mcsharry||Director||Sell||697||$145.20||$101,204.40|| |
|5/16/2016||Michael Patrick Miller||SVP||Sell||100||$145.20||$14,520.00|| |
|4/25/2016||Karen J Wilson||SVP||Sell||604||$160.00||$96,640.00|| |
|4/15/2016||Michael Patrick Miller||SVP||Sell||100||$145.79||$14,579.00|| |
|4/13/2016||Karen J Wilson||SVP||Sell||5,007||$150.00||$751,050.00|| |
|4/12/2016||Russell J Cox||COO||Sell||4,000||$136.98||$547,920.00|| |
|4/7/2016||Karen J Wilson||SVP||Sell||2,161||$140.90||$304,484.90|| |
|3/15/2016||Michael Patrick Miller||SVP||Sell||100||$129.17||$12,917.00|| |
|3/8/2016||Bruce C Cozadd||CEO||Sell||2,500||$126.04||$315,100.00|| |
|2/29/2016||Paul Treacy||SVP||Sell||354||$123.48||$43,711.92|| |
|2/23/2016||Seamus Mulligan||Director||Sell||27,968||$122.71||$3,431,953.28|| |
|2/16/2016||Michael Patrick Miller||SVP||Sell||100||$115.63||$11,563.00|| |
|2/10/2016||Patrick G Enright||Director||Sell||10,000||$117.92||$1,179,200.00|| |
|2/9/2016||Bruce C Cozadd||CEO||Sell||2,500||$111.37||$278,425.00|| |
|1/15/2016||Michael Patrick Miller||SVP||Sell||100||$122.66||$12,266.00|| |
|1/12/2016||Bruce C Cozadd||CEO||Sell||2,500||$123.81||$309,525.00|| |
|1/5/2016||Patrick G Enright||Director||Sell||10,000||$138.09||$1,380,900.00|| |
|12/15/2015||Michael Patrick Miller||SVP||Sell||100||$136.99||$13,699.00|| |
|12/8/2015||Bruce C Cozadd||CEO||Sell||2,500||$139.72||$349,300.00|| |
|12/2/2015||Patrick G Enright||Director||Sell||10,424||$146.67||$1,528,888.08|| |
|11/23/2015||Seamus Mulligan||Director||Sell||27,968||$145.86||$4,079,412.48|| |
|11/10/2015||Bruce C Cozadd||CEO||Sell||2,500||$128.53||$321,325.00|| |
|11/10/2015||Patrick G Enright||Director||Sell||10,000||$135.29||$1,352,900.00|| |
|10/21/2015||Suzanne Sawochka Hooper||EVP||Sell||2,000||$125.00||$250,000.00|| |
|10/13/2015||Bruce C Cozadd||CEO||Sell||2,500||$131.50||$328,750.00|| |
|10/5/2015||Patrick G Enright||Director||Sell||10,000||$133.79||$1,337,900.00|| |
|9/25/2015||Michael Patrick Miller||SVP||Sell||100||$145.23||$14,523.00|| |
|9/8/2015||Bruce C. Cozadd||CEO||Sell||2,500||$163.07||$407,675.00|| |
|9/1/2015||Patrick G Enright||Director||Sell||10,000||$165.99||$1,659,900.00|| |
|7/14/2015||Bruce C Cozadd||CEO||Sell||5,000||$177.79||$888,950.00|| |
|7/14/2015||Suzanne Sawochka Hooper||EVP||Sell||4,000||$177.79||$711,160.00|| |
|7/6/2015||Patrick G Enright||Director||Sell||10,000||$177.11||$1,771,100.00|| |
|6/9/2015||Bruce C Cozadd||CEO||Sell||5,000||$173.16||$865,800.00|| |
|6/9/2015||Suzanne Sawochka Hooper||EVP||Sell||4,000||$173.16||$692,640.00|| |
|6/2/2015||Karen J Wilson||SVP||Sell||5,751||$179.59||$1,032,822.09|| |
|6/1/2015||Karen J Wilson||SVP||Sell||5,494||$179.57||$986,557.58|| |
|4/14/2015||Bruce C Cozadd||CEO||Sell||5,000||$181.45||$907,250.00|| |
|4/14/2015||Suzanne Sawochka Hooper||EVP||Sell||4,000||$181.45||$725,800.00|| |
|3/25/2015||Seamus Mulligan||Director||Sell||50,000||$174.59||$8,729,500.00|| |
|1/5/2015||Patrick G Enright||Director||Sell||10,000||$160.25||$1,602,500.00|| |
|12/26/2014||Seamus Mulligan||Director||Sell||50,000||$163.40||$8,170,000.00|| |
|12/12/2014||Patrick G Enright||Director||Sell||2,343||$170.98||$400,606.14|| |
|12/9/2014||Bruce C Cozadd||CEO||Sell||5,000||$178.79||$893,950.00|| |
|12/9/2014||Suzanne Sawochka Hooper||EVP||Sell||1,852||$178.79||$331,119.08|| |
|12/1/2014||Patrick G Enright||Director||Sell||10,000||$172.74||$1,727,400.00|| |
|11/24/2014||Jeffrey K Tobias||CMO||Sell||4,598||$170.12||$782,211.76|| |
|11/7/2014||Iain Mcgill||SVP||Sell||7,066||$172.03||$1,215,563.98|| |
|10/10/2014||Jeffrey K Tobias||CMO||Sell||1,000||$154.04||$154,040.00|| |
|10/6/2014||Patrick G Enright||Director||Sell||10,000||$160.56||$1,605,600.00|| |
|9/25/2014||Seamus Mulligan||Director||Sell||50,000||$163.16||$8,158,000.00|| |
|9/24/2014||Seamus Mulligan||Director||Sell||35,294||$163.70||$5,777,627.80|| |
|9/12/2014||Jeffrey K Tobias||CMO||Sell||1,000||$171.22||$171,220.00|| |
|9/11/2014||Karen J Wilson||SVP||Sell||3,000||$175.00||$525,000.00|| |
|9/11/2014||Seamus Mulligan||Director||Sell||50,000||$175.00||$8,750,000.00|| |
|9/9/2014||Bruce C Cozadd||CEO||Sell||5,000||$170.32||$851,600.00|| |
|9/8/2014||Karen J Wilson||SVP||Sell||2,500||$170.00||$425,000.00|| |
|9/8/2014||Suzanne Sawochka Hooper||EVP||Sell||1,852||$168.00||$311,136.00|| |
|8/12/2014||Bruce C Cozadd||CEO||Sell||5,000||$133.15||$665,750.00|| |
|8/12/2014||Suzanne Sawochka Hooper||EVP||Sell||1,185||$133.15||$157,782.75|| |
|8/11/2014||Jeffrey K Tobias||CMO||Sell||4,933||$135.42||$668,026.86|| |
|7/8/2014||Bruce C Cozadd||CEO||Sell||5,000||$155.00||$775,000.00|| |
|7/8/2014||Suzanne Sawochka Hooper||EVP||Sell||1,853||$155.00||$287,215.00|| |
|7/7/2014||Karen J Wilson||SVP||Sell||2,500||$165.00||$412,500.00|| |
|6/25/2014||Seamus Mulligan||Director||Sell||50,000||$149.69||$7,484,500.00|| |
|6/20/2014||Russell J Cox||COO||Sell||2,000||$155.00||$310,000.00|| |
|6/17/2014||Fintan Keegan||EVP||Sell||3,750||$150.00||$562,500.00|| |
|6/10/2014||Bruce C Cozadd||CEO||Sell||5,000||$142.34||$711,700.00|| |
|5/16/2014||Jeffrey Tobias||CMO||Sell||1,000||$128.01||$128,010.00|| |
|5/13/2014||Bruce Cozadd||CEO||Sell||5,000||$128.92||$644,600.00|| |
|4/17/2014||Rick Winningham||Director||Sell||27,500||$140.00||$3,850,000.00|| |
|4/14/2014||Jeffrey Tobias||CMO||Sell||3,000||$128.54||$385,620.00|| |
|4/8/2014||Bruce Cozadd||CEO||Sell||5,000||$123.18||$615,900.00|| |
|3/10/2014||Jeffrey Tobias||CMO||Sell||3,000||$152.99||$458,970.00|| |
|3/6/2014||Fintan Keegan||EVP||Sell||4,640||$159.90||$741,936.00|| |
|3/4/2014||Seamus Mulligan||Director||Sell||550,000||$156.25||$85,937,500.00|| |
|3/3/2014||Patrick Enright||Director||Sell||559,628||$152.39||$85,281,710.92|| |
Latest Headlines for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)
Jazz Pharmaceuticals PLC (NASDAQ JAZZ) Chart for Friday, November, 24, 2017